cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
pharma · Colorectal Neoplasms · Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang Rongyao Biotech
Zhejiang University
Zhejiang Rongyao Biotech drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
1999 Founded
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 1999
- Employees
- 5
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Zhejiang Rongyao Biotech pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zhejiang Rongyao Biotech drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
fruquintinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Zhejiang Rongyao Biotech in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor